3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Brain Neoplasms
1902
Glioblastoma
1795
Glioma
1127
Central Nervous System Neoplasms
599
Astrocytoma
593
Neuroblastoma
552
Gliosarcoma
465
Oligodendroglioma
363
Neoplasms
312
Breast Neoplasms
273
Medulloblastoma
272
Carcinoma, Non-Small-Cell Lung
226
Recurrence
199
Sarcoma
183
Neoplasm Metastasis
183
Melanoma
181
Meningioma
177
Ependymoma
175
Lung Neoplasms
157
Lymphoma
133
Osteosarcoma
126
Meningeal Carcinomatosis
126
Neurofibromatosis 1
114
Wilms Tumor
111
Ovarian Neoplasms
110
Diffuse Intrinsic Pontine Glioma
105
Precursor Cell Lymphoblastic Leukemia-Lymphoma
103
Rhabdomyosarcoma
100
Lymphoma, Non-Hodgkin
96
Burkitt Lymphoma
89
Interventions
brolucizumab
1
aflibercept
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Macular Degeneration
×
CNS
×
Clear all
NCT03710564
2023-01-30
MERLIN
Novartis
Phase 3
Terminated
535 enrolled
14 charts